Economic growth is driven by innovation. “Fortune favours the bold,” as the proverb goes. And there has seldom been a better — or more urgent — moment to be bold, particularly in Britain’s life sciences sector.
We have the potential to be a global leader and innovator in the industry, thanks to some of the country’s unique strengths. We have strong entrepreneurial and academic bases that collaborate well, as shown by the rapid development of the Covid-19 vaccine. We are small enough to be nimble yet big enough to have an impact.
Our regulators are helpful, not obstructive, when it comes to the development of new medicines. Dame June Raine, the head of the Medicines and Healthcare products Regulatory Agency (MHRA), wants the regulator to
